3,5-Diethyl-4-[6-(4-methoxy-2-nitrophenoxy)hexyl]isoxazole | 79842-84-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-Diethyl-4-[6-(4-methoxy-2-nitrophenoxy)hexyl]isoxazole
• 英文别名: 3,5-diethyl-4-[6-(4-methoxy-2-nitrophenoxy)hexyl]-1,2-oxazole
• CAS: 79842-84-5
• 化学式: C₂₀H₂₈N₂O₅
• 分子量: 376.453
• InChiKey: FKBFGOQSALTSKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  90.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-[6-(4-methoxy-2-nitrophenoxy)hexyl]-3,5-heptanedione 在 盐酸羟胺 作用下， 以 吡啶 为溶剂， 生成 3,5-Diethyl-4-[6-(4-methoxy-2-nitrophenoxy)hexyl]isoxazole
  参考文献：
  名称：

  4-(Arylaliphatic)isoxazoles

  摘要：

  具有抗病毒活性的4-(芳基脂肪)异噁唑可通过将羟胺与化学式为Ar-Y-CH(CO-R).sub.2的二酮反应制备，其中Ar为取代苯基，Y为(CH.sub.2).sub.n或O(CH.sub.2).sub.n，而R为较低的烷基。

  公开号：

  US04268678A1

文献信息

• 4-(Arylaliphatic)isoxazoles
  申请人：Sterling Drug Inc.

  公开号：US04268678A1

  公开（公告）日：1981-05-19

  4-(Arylaliphatic)isoxazoles, having antiviral activity, are prepared by reacting with hydroxylamine a diketone of the formula Ar-Y-CH(CO-R).sub.2, wherein Ar is substituted phenyl, Y is (CH.sub.2).sub.n or O(CH.sub.2).sub.n, and R is lower-alkyl.

  具有抗病毒活性的4-(芳基脂肪)异噁唑可通过将羟胺与化学式为Ar-Y-CH(CO-R).sub.2的二酮反应制备，其中Ar为取代苯基，Y为(CH.sub.2).sub.n或O(CH.sub.2).sub.n，而R为较低的烷基。
• DIANA, G. D.;MCKINLAY, M. A.;BRISSON, C. J.;ZALAY, E. S.;MIRALLES, J. V.;+, J. MED. CHEM., 1985, 28, N 6, 748-752
  作者：DIANA, G. D.、MCKINLAY, M. A.、BRISSON, C. J.、ZALAY, E. S.、MIRALLES, J. V.、+

  DOI：——

  日期：——
• US4268678A
  申请人：——

  公开号：US4268678A

  公开（公告）日：1981-05-19
• Ellipticine derivatives with an affinity to the estrogen receptor. An approach to develop intercalating drugs with a specific effect on the hormone-dependent breast cancer
  作者：Alain Delbarre、Robert Oberlin、Bernard P. Roques、Jean Louis Borgna、Henri Rochefort、Jean Bernard Le Pecq、Alain Jacquemin-Sablon

  DOI：10.1021/jm00383a011

  日期：1985.6

  In order to obtain breast tumor directed agents, we have prepared mixed compounds using estradiol or (E)-clomiphene as specific vectors of the breast tissue and a DNA intercalator from the ellipticine series as the cytotoxic agent. Among the newly synthesized ellipticine derivatives, only the 2-[3-aza-5-(3,17 beta-dihydroxy-1,3,5-estratrien-17 alpha-yl)-4-oxopentamethylene]ellipticinium bromide shows the desired properties, DNA intercalation and affinity for estrogen receptor. Competition experiments with estradiol on the hormone-dependent human MCF-7 breast cancer cell line demonstrate that a transport by the estrogen receptor system is not involved in the antitumor activity of derivative 24.